Back to School: How biopharma can reboot drug development. Access exclusive analysis here

American Oriental, Changchun Xinan Pharmaceutical Group Co. Ltd. deal

AOB acquired Changchun for $28.5 million in

Read the full 72 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE